– 77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years – – Initiation of Ocrevus ...

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...

TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Phase 3 trial. Briumvi's intravenous administration ...

Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st ...

Briumvi (ublituximab-xiiy) and Ocrevus (ocrelizumab) are prescription drugs used to treat certain types of multiple sclerosis (MS). Both drugs are given as an intravenous (IV) infusion by a healthcare ...

10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS) 10-year safety data ...

Genentech, a member of Roche (RHHBY), presented new data for Ocrevus and the investigational Bruton’s tyrosine kinase inhibitor fenebrutinib at the 41st Congress of the European Committee for ...

Ocrevus (ocrelizumab) is a prescription drug that treats certain types of multiple sclerosis (MS) in adults by lowering B cell levels. Your response to this drug may vary based on your medical history ...

SOUTH SAN FRANCISCO, Calif., September 24, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the ...

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMS ...